🇺🇸 FDA
Patent

US 11007183

Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors

granted A61KA61K31/4439A61K31/506

Quick answer

US patent 11007183 (Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors) held by Biomed Valley Discoveries, Inc. expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Biomed Valley Discoveries, Inc.
Grant date
Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/4439, A61K31/506, A61K31/5377, A61K45/06